Held by 1 specialist biotech fund
1 fund opened new positions. Next phase3 readout (2.0 mg OPT-302): Mar 2025. Short interest: 0.4% of float.
See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.